This MedLibrary.org supplementary page on Pholcodine is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Pholcodine
|
|
| Systematic (IUPAC) name | |
| 7,8-didehydro-4,5α-epoxy-17-methyl-3- [2-(morpholin-4-yl)ethoxy]morphinan-6α-ol |
|
| Identifiers | |
| CAS number | |
| ATC code | R05 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C23H30N2O4 |
| Mol. mass | 398.55 g/mol |
| Pharmacokinetic data | |
| Bioavailability | Maximum plasma conc. attained 4-8 hours after oral dose. |
| Protein binding | 23.5% |
| Metabolism | Hepatic |
| Half life | 32-43 hours; volume of distribution is 36-49L/kg. |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
A(AU) |
| Legal status |
Class B(UK) Schedule I(US) OTC (UK) |
| Dependence Liability | Low |
| Routes | Oral |
Pholcodine is a drug which is an opioid cough suppressant (antitussive). It helps suppress unproductive coughs and also acts as an antifungal agent. It also has a mild sedative effect, but has little or no analgesic effects. It is also known as morpholinylethylmorphine.
Pholcodine is found in certain cough lozenges. [1] However, in the UK, the preparation is almost exlusively an oral solution, typically 5 mg / 5 ml. Adult dosage is 5-10ml up to 3-4 times daily1. Pholcodeine now largely replaces the previously more common codeine linctus, as it has a much lower potential for dependence.
Contents |
Mechanism of action
Pholcodine is readily absorbed from the gastrointestinal tract and freely crosses the blood-brain barrier. It acts primarily on the central nervous system (CNS), causing depression of the cough reflex, partly by a direct effect on the cough centre in the medulla. It is metabolized in the liver and its action may be prolonged in individuals with hepatic insufficiency (i.e. liver problems). Its use is therefore contraindicated in patients with liver disease, while care is advised in patients with hepatic impairement.
Side effects
Side effects are rare and may include dizziness and gastrointestinal disturbances such as nausea or vomiting.
Adverse effects such as constipation, drowsiness, excitation, ataxia and respiratory depression have been reported occasionally or after large doses.
A Norwegian cough-syrup containing pholcodine ("Tuxi") has been withdrawn from the market because it caused increased levels of IgE-antibodies, regardless of an actual allergy to the drug. This is believed to increase the risk of anaphylaxis to neuromuscular blocking agents used during anaesthesia.
See also
References
- ^ BNF (2007). British National Formulary 54. BMJ Publishing Group Ltd., RPS Publishing, London. Page 175.
External links
- Australian Therapeutic Goods Admission document on Pholcodine (Rich Text Format)
|
||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 25 October 2008, at 12:08.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Pholcodine".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.